1229006-36-3

Upstream product

• 201230-82-2 carbon monoxide 
• 1229006-35-2 C₁₈H₁₇BrN₂O₄ 
• 140-75-0 para-fluorobenzylamine 
• 1206102-04-6 2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one 
• 1229006-11-4 C₂₀H₁₆O₃ 
• 119736-16-2 3-(benzyloxy)-1-((tert-butoxycarbonyl)amino)-4-oxo-1,4-dihydropyridine-2-carboxylic acid ethyl ester 
• 500371-01-7 3-(benzyloxy)-4-oxo-4H-pyran-2-carbaldehyde 
• 1229006-31-8 C₁₆H₁₅NO₄ 
• 1229006-32-9 C₁₇H₁₇NO₄ 
• 1229006-33-0 C₁₇H₁₉NO₆ 
• 100-39-0 benzyl bromide 
• 1229006-34-1 C₁₈H₁₈N₂O₄ 
• 61049-69-2 3-O-benzylmaltol 
• 1421314-66-0 5-benzyloxy-N-(4-fluorobenzyl)-6-hydroxymethyl-4-oxo-1,4-dihydropyridine-3-carboxamide 

Downstream Products

• 1421314-81-9 (R)-N-(4-fluorobenzyl)-7-hydroxy-6,8-dioxo-3,4,6,8,12,12ahexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide 
• 1421314-82-0 (S)-N-(4-fluorobenzyl)-7-hydroxy-6,8-dioxo-3,4,6,8,12,12ahexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide 

Relevant academic research and scientific papers

Intermediate of these pyridonecarboxylic carbamoylalkanoic and HIV integrase inhibitor

A synthesis approach providing an early ring attachment via a bromination to compound I-I yielding compound II-II: whereby a final product such as AA: can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q.

Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles

This work is a continuation of our initial discovery of a potent monocyclic carbamoyl pyridone human immunodeficiency virus type-1 (HIV-1) integrase inhibitor that displayed favorable antiviral and pharmacokinetic properties. We report herein a series of

PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS

Processes are provided which create an aldehyde methylene, or hydrated or hemiacetal methylene attached to a heteroatom of a 6 membered ring without going through an olefinic group and without the necessity of using an osmium reagent. In particular, a comopound of formula (I) can be produced from (II) and avoid the use of an allyl amine: (formulae I and II) where R, P 1 P3, R3 and Rx are as described herein.